



PRESS RELEASE

ONCODESIGN wins the 4th European Small and Mid-Cap Awards in the “Rising Star” category

Dijon, France, November 21, 2016 - ONCODESIGN (FR0011766229 - ALONC), a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, won the 4th European Small and Mid-Cap Awards in the “Rising Star” category. The award was presented to ONCODESIGN at a ceremony in Brussels on November 17, 2016.

The European Small and Mid-Cap Awards were set up to highlight the best European Small and Mid-Sized Companies that have gained access to capital markets via an Initial Public Offering (IPO). This is a joint initiative of the European Commission, leading European securities exchanges and EuropeanIssuers.

The four winners were chosen by an independent jury from amongst a very high standard of entries from across Europe.

ONCODESIGN wins the Rising Star Award. The winner of the Rising Star Award stands out as an exceptional performer in the sub-group of SMEs. The Rising Star is also a responsible corporate citizen. It is an emerging business and one that has clearly furthered growth potential. It is well-managed and have been resourceful with the proceeds of flotation.

“We are very proud to receive this award. It is a recognition for all employees of ONCODESIGN without whom we would not have come to this stage. All of us share one mission: to discover new innovative treatments for cancer and serious diseases patients with no known therapies,” said Dr Philippe Genne, CEO and founder of ONCODESIGN.

About FESE

The Federation of European Securities Exchanges (FESE) represents 36 exchanges in equities, bonds, derivatives and commodities through 20 full members from 30 countries, as well as one Affiliate Member and one Observer Member. For further information please visit www.fese.eu

About EuropeanIssuers

EuropeanIssuers is a pan-European organisation representing the interests of publicly quoted companies across Europe to the EU Institutions. We seek capital markets that serve the interests of their end users, including issuers. For more information, please visit www.europeanissuers.eu

About the European Commission

The Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) of the European Commission develops and implements a range of policies to improve access to finance for SMEs in the EU. SMEs are critical to European economic recovery and to accomplishing the EU’s goals of job creation, competitiveness and growth. For more information, please visit http://ec.europa.eu/growth/access-to-finance_en

About Oncodesign: www.oncodesign.com

Founded over 20 years ago by Dr Philippe Genne, the Company's CEO and Chairman, Oncodesign is a biotechnology company that maximises the pharmaceutical industry's chances of success in discovering new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment. With its unique experience acquired by working with more than 600 clients, including the world's largest pharmaceutical companies, along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, advanced animal modelling and medical imaging, Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, which represent a market estimated at over \$40 billion in 2016 and accounting for almost 25% of the pharmaceutical industry's R&D expenditure, Oncodesign's technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb, Ipsen and UCB. Oncodesign is based in Dijon, France, in the heart of the town's university and hospital hub. It has 108 employees and subsidiaries in Canada and the USA.

Contacts

Oncodesign

Philippe Genne

Chairman and CEO

Tel: +33 (0)3 80 78 82 60

investisseurs@oncodesign.com

NewCap

Investor & Press Relations

Julien Perez / Nicolas Merigeau

Tel: +33 (0)1 44 71 98 52

oncodesign@newcap.eu

ALONC
LISTED
ALTERNEXT